Michael Kunz

ORCID: 0000-0001-9666-2209 · 2 papers in corpus
nonrandomized-trial 2012
Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women
Contraception ·doi:10.1016/j.contraception.2012.01.010

BACKGROUND: We evaluated the effects of cytochrome P450 3A4 (CYP3A4) induction and inhibition on steady-state pharmacokinetics of the components of a novel oral contraceptive (OC) containing estradiol valerate (E₂V) and dienogest (DNG). ST…

rct 2007
A one-year randomized double-blind, multicentre study to evaluate the effects of an oestrogen-reduced, continuous combined hormone replacement therapy preparation containing 1 mg oestradiol valerate and 2 mg dienogest on metabolism in postmenopausal women
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception ·doi:10.1080/13625180701441030

OBJECTIVES: To evaluate the impact of an oestrogen-reduced, continuous combined hormone replacement therapy preparation containing 1 mg oestradiol valerate (1EV) and 2 mg dienogest (2DNG) on metabolism. METHODS: In a randomized double-blin…